Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin

Jones-Trower, Agnes; García, Alonzo D.; Meseda, Clement A.; He, Yong; Weiss, Carol D.; Kumar, Arunima; Weir, Jerry P.; Merchlinsky, Michael

doi:10.1016/j.virol.2005.08.008

Cited by 44 publications

(59 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this assay, 95% (20/21) of monkeypox-immune participants (including 2/3 who had clinically inapparent cases) reacted with at least 1 diagnostic protein band. A cluster of 33 kDa-to 42 kDavaccinia proteins was previously described as immunoreactive with pooled human vaccinia immune globulin (27). This cluster was also evident in the current study (Figure 2, panels B and C), although detection and intensity of bands within this cluster varied among persons.…”

Section: Discussionsupporting

confidence: 84%

“…Historically, several serologic techniques have been used to identify orthopoxvirus infections, including hemagglutination-inhibition (13), gel precipitation (17,22,23), complement fi xation (22), cross-neutralization (14), immunofl uorescence (24,25), Western blot (26,27), radioimmunoassay (13,15), and ELISA (28,29). In previous studies, we used a peptide-based ELISA with peptide sequences from the monkeypox B21R gene to differentially diagnose monkeypox infection (6).…”

Section: Discussionmentioning

confidence: 99%

“…It has only modest value as a stand-alone diagnostic test because of <90% sensitivity and specifi city overall, but may be useful for confi rming cases of monkeypox identifi ed by other virologic or serologic approaches. Relative to standard Western blot approaches (26,27), preadsorption of plasma with vaccinia antigens decreased the intensity and detection of cross-reactive proteins and enabled easier identifi cation of 3 diagnostic protein bands (39, 124, and 148 kDa). In this assay, 95% (20/21) of monkeypox-immune participants (including 2/3 who had clinically inapparent cases) reacted with at least 1 diagnostic protein band.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Retrospective Analysis of Monkeypox Infection

Dubois

2008

Emerg. Infect. Dis.

View full text Add to dashboard Cite

Serologic cross-reactivity between orthopoxviruses is a substantial barrier to laboratory diagnosis of specifi c orthopoxvirus infections and epidemiologic characterization of disease outbreaks. Historically, time-consuming and laborintensive strategies such as cross-adsorbed neutralization assays, immunofl uorescence assays, and hemagglutination-inhibition assays have been used to identify orthopoxvirus infections. We used cross-adsorption to develop a simple and quantitative postadsorption ELISA for distinguishing between monkeypox and vaccinia infections. Despite the diffi culty of diagnosing clinically inapparent monkeypox in previously vaccinated persons, this technique exhibited 100% sensitivity and 100% specifi city for identifying clinically overt monkeypox infection irrespective of vaccination history. We also describe a Western blot technique in which up to 3 diagnostic bands may be used to distinguish between vaccinia and monkeypox infection. The techniques described provide independent diagnostic tests suitable for retrospective analysis of monkeypox outbreaks.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Retrospective Analysis of Monkeypox Infection

Dubois

2008

Emerg. Infect. Dis.

View full text Add to dashboard Cite

show abstract

“…Recent studies suggest that MVA does not produce all the major vaccinia proteins targeted by VIG [18]. These investigators determined one protein to be the vaccinia gene fragment corresponding to the cowpox A-type inclusion body.…”

Section: Discussionmentioning

confidence: 99%

Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challenge

Frey

Newman

Kennedy

et al. 2007

Vaccine

112

115

View full text Add to dashboard Cite

Smallpox vaccination with replication deficient vaccinia strains such as Modified Vaccinia-Ankara (MVA) may induce protective immunity with improved safety and tolerability profiles compared with currently available smallpox vaccines. Ninety subjects were randomized equally to 6 groups in a partially blinded, randomized control clinical trial. IMVAMUNE ® (MVA-BN ® , Bavarian Nordic A/S, Kvistgård, Denmark) vaccine or placebo was administered at Study Day 0 and 28 by subcutaneous or intramuscular injection and five groups were challenged with Dryvax ® at study Day 112. Vaccination with two doses of IMVAMUNE ® was safe and well-tolerated compared to Dryvax ® . IMVAMUNE ® produced comparable cellular and humoral immune responses to one dose of Dryvax ® and the immunity induced appears robust 90 days post vaccination by evidence of attenuated primary cutaneous reaction responses following Dryvax ® . IMVAMUNE ® vaccination prior to Dryvax ® reduced virus replication at the Dryvax ® site, decreased the size of the primary cutaneous lesion, and decreased the time to healing but did not completely ameliorate the immune response. MO 63110,, E-mail address: E-mail: freyse@slu.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. In a recent study, IMVAMUNE ® , a highly attenuated vaccinia strain derived from MVA-572 (obtained from Dr. Anton Mahr), does not replicate in human cells and was safe and immunogenic in humans [9]. The present study sought to evaluate the safety and immunogenicity of a range of doses and routes of administration of IMVAMUNE ® . Potential surrogate efficacy of MVA-induced immune responses was evaluated by the ability of two doses of IMVAMUNE ® to reduce the clinical effects of a Dryvax ® challenge. Keywords NIH Public Access Author Manuscript Methods Vaccines and DiluentsIMVAMUNE ® (Bavarian Nordic A/S, Kvistgård, Denmark), a modified vaccinia Ankara vaccine (lot no. 130303), is a non-replicating virus in human cells used as the MVA smallpox vaccine in this study. Lyophilized vaccine was reconstituted with sterile water for injection (WFI) (Impfstoffwerk Dessau-Thornau GmbH, Germany). The reconstituted vaccine contains approximately 2 × 10 8 TCID 50 per ml. The placebo was sterile saline for injection (American Regent Laboratories, Inc, Shirley, NY). Licensed smallpox vaccine (Dryvax ® , Wyeth Laboratories, Marietta, PA) (lot no. 4008284), a replicating vaccinia virus provided by the Centers for Disease Control and Prevention in Atlanta, GA, was used as both the comparator vaccine and the virus in the challenge portion of this study.Reconstituted IM...

show abstract

“…The importance of including A27L, D8L, and B5R as components of a subunit smallpox vaccine is underscored by the detection of antibody responses to both IMV-and EEV-associated proteins in the sera of humans immunized with Dryvax (25) or vaccinia virus strain Lister (36). Studies with nonhuman primates or mice have also demonstrated that immunization with baculovirus-expressed recombinant proteins or DNA vaccines composed of different combinations of IMV-and EEVassociated proteins-such as A33R, B5R, and L1R (14,15), A27L, A33R, L1R, and B5R (21), or A27L, B5R, L1R, A33R, and D8L (41)-result in the induction of high levels of neutralizing antibodies and in the protection of mice from lethal challenge with vaccinia virus.…”

mentioning

confidence: 99%